Aggressive B-Cell Lymphoma
The latest news, research, and perspectives in aggressive B-cell lymphoma. These fast-growing non-Hodgkin lymphomas, including diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma, arise at different stages of B-cell development.
Advertisement
The positive safety profile of this bispecific antibody makes it well-suited for combination with other treatments.
Brentuximab vedotin plus lenalidomide and rituximab combination showed promising efficacy and potential as bridging therapy.
The approval is based on results from the phase I ELM-1 and phase II ELM-2 trials.
Tafasitamab is a humanized, Fc-modified monoclonal antibody that targets the CD19 antigen.
A retrospective study has found an association between post-CAR-T sC5b-9 levels and ICANS occurrence following CAR-T.
These findings concern axi-cel use in relapsed and refractory primary and secondary disease.
Advertisement
Patients with relapsed refractory LBCL can derive clinical benefit from liso-cel NCP without compromising safety.
Dr. Bertoni and colleagues characterized two small nucleolar RNAs that exert tumor suppressor activity in DLBCL cells.
Adding ofatumumab to reduced intensity conditioning is safe and effective in high-risk B-cell non-Hodgkin lymphoma.
The approval was declined due to the enrollment status of the confirmatory trials.
This manufacturing process change results in a shorter manufacturing time for axi-cel from 16 days to 14 days.
ZUMA-7 showed that axi-cel significantly improved OS compared with standard of care in relapsed or refractory LBCL.
Dr. Eyre and the hosts discuss lymphoma abstracts from ASH 2023, including the FLAIR trial and the SYMPATICO trial.
The study included 16 baseline and 18 post-infusion tumor samples from 26 patients.
In this episode of The HemOnc Pulse, Alan Skarbnik, MD, of Novant Health, discusses practice-changing research in DLBCL.
The results were presented at the 65th American Society of Hematology Annual Meeting & Exposition in San Diego.
Researchers collected serial peripheral blood mononuclear cell samples from patients with R/R LBCL treated with axi-cel.
The phase II, multicenter, single-arm study is assessing axi-cel for frontline treatment in patients with high-risk LBCL.
The analysis assessed the impacts of bridging therapy when used in patients receiving axi-cel for large B-cell lymphoma.
Dr. Spiegel shared five-year data from a retrospective study of 298 patients with LBCL who received axi-cel.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.